- Home
- CRVS vs DBI Comparison
CRVS vs DBI Comparison
Compare CRVS & DBI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRVS
- DBI
- Stock Information
- Founded
- CRVS 2014
- DBI 1991
- Country
- CRVS United States
- DBI United States
- Employees
- CRVS N/A
- DBI N/A
- Industry
- CRVS Biotechnology: Pharmaceutical Preparations
- DBI Clothing/Shoe/Accessory Stores
- Sector
- CRVS Health Care
- DBI Consumer Discretionary
- Exchange
- CRVS Nasdaq
- DBI Nasdaq
- Market Cap
- CRVS 257.0M
- DBI 222.4M
- IPO Year
- CRVS 2016
- DBI 1991
- Fundamental
- Price
- CRVS $2.99
- DBI $2.99
- Analyst Decision
- CRVS Strong Buy
- DBI Hold
- Analyst Count
- CRVS 5
- DBI 2
- Target Price
- CRVS $12.63
- DBI $4.75
- AVG Volume (30 Days)
- CRVS 715.8K
- DBI 1.8M
- Earning Date
- CRVS 05-05-2025
- DBI 03-20-2025
- Dividend Yield
- CRVS N/A
- DBI 6.69%
- EPS Growth
- CRVS N/A
- DBI N/A
- EPS
- CRVS N/A
- DBI N/A
- Revenue
- CRVS N/A
- DBI $3,009,262,000.00
- Revenue This Year
- CRVS N/A
- DBI $3.51
- Revenue Next Year
- CRVS N/A
- DBI $2.60
- P/E Ratio
- CRVS N/A
- DBI N/A
- Revenue Growth
- CRVS N/A
- DBI N/A
- 52 Week Low
- CRVS $1.30
- DBI $2.87
- 52 Week High
- CRVS $10.00
- DBI $11.06
- Technical
- Relative Strength Index (RSI)
- CRVS 26.38
- DBI 33.36
- Support Level
- CRVS $3.06
- DBI $3.71
- Resistance Level
- CRVS $3.31
- DBI $3.99
- Average True Range (ATR)
- CRVS 0.36
- DBI 0.34
- MACD
- CRVS -0.10
- DBI -0.01
- Stochastic Oscillator
- CRVS 1.11
- DBI 7.72
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical engaged in developing drugs and antibodies that target the critical cellular elements of the immune system. It focuses on the development of immune modulator product candidates to treat COVID-19, T-cell lymphomas, other cancers, and autoimmune diseases. The company's primary product candidate is Soquelitinib (CPI-818), an oral, small-molecule drug that selectively inhibits ITK (interleukin-2-inducible T cell kinase). The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).
About DBI Designer Brands Inc.
Designer Brands Inc is a designer, producer, and retailer of footwear and accessories. The company operates in three reportable segments: the U.S. Retail segment, the Canada Retail segment, and the Brand Portfolio segment. The U.S. Retail segment operates the DSW Designer Shoe Warehouse banner through its direct-to-consumer U.S. stores and e-commerce site. The Canada Retail segment operates The Shoe Company and DSW banners through its direct-to-consumer Canada stores and e-commerce sites. The Brand Portfolio segment earns revenue from the sale of wholesale products to retailers, commissions for serving retailers as the design and buying agent for products under private labels, and the sale of branded products through its direct-to-consumer e-commerce sites.